Compare · CYAN vs GRPH

CYAN vs GRPH

Side-by-side comparison of Cyanotech Corporation (CYAN) and Graphite Bio Inc. (GRPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CYAN and GRPH operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • GRPH has more recent analyst coverage (16 ratings vs 0 for CYAN).
MetricCYANGRPH
Company
Cyanotech Corporation
Graphite Bio Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2021
News (4w)
0
0
Recent ratings
0
16
CYAN

Cyanotech Corporation

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.

GRPH

Graphite Bio Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Latest CYAN

Latest GRPH